NEUROCRINE BIOSCIENCES INC

Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, dedicated to discovering, developing, and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders. The company's product portfolio includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids, the latter in collaboration with AbbVie Inc. Neurocrine Biosciences launched INGREZZA (valbenazine) in the U.S. in May 2017 for TD and in August 2023 for chorea associated with Huntington's disease. The company also launched CRENESSITY (crinecerfont) in the U.S. in December 2024 for CAH. The company estimates that TD affects approximately 800,000 people in the U.S., approximately 90% of the 40,000 people in the U.S. affected by Huntington's disease will develop chorea, and CAH affects at least 20,000 people in the U.S. INGREZZA net product sales were $2.51 billion for 2025, $2.31 billion for 2024, and $1.84 billion for 2023, representing a significant portion of total net product sales in each of these years. CRENESSITY net product sales were $301.2 million for 2025. The company's commercial products include treatments for Tardive Dyskinesia in the U.S., Japan, and select Asian markets; Chorea Associated with Huntington's Disease; Classic Congenital Adrenal Hyperplasia in the U.S.; and Endometriosis and Uterine Fibroids in the U.S. The company also has a diversified portfolio of multiple compounds in mid- to late-phase development and an expanding early-phase pipeline.